Novo Nordisk A

vorige Seite Seite 1 von 8 nächste Seite

Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities

Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg.

OTE0001
13.05.2021 07:00
 

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment …

OTE0003
26.03.2021 14:23
 

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention.

OTE0007
23.03.2021 20:46
 

Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy

Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss …

OTE0007
05.11.2020 16:07
 

Umstellung von anderen Basalinsulinen auf einmal wöchentlich verabreichtes Insulin Icodec hat sich in Phase 2-Studie bei Menschen mit Typ-2-Diabetes als wirkungsvoll und gut verträglich erwiesen

Novo Nordisk gab heute die Ergebnisse von drei klinischen Phase-2-Studien für Insulin Icodec, ein einmal wöchentlich zu verabreichendes Basalinsulin-Analogon, bekannt, die während der 56. Jahrestagung …

OTS0145
24.09.2020 12:29
 
OTE0001
15.06.2020 01:31
 

Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged …

OTE0004
31.03.2020 18:01
 

Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off

Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim …

OTE0007
01.10.2019 19:40
 

Tresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower …

OTE0003
19.09.2019 12:03
 

Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels

Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across …

OTE0003
17.09.2019 15:02
 

Fiasp® Demonstrated Effective Overall Blood Sugar Reductions in People With Advanced Type 2 Diabetes Uncontrolled on Multiple Daily Injections (Basal-bolus Regimen)

New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not …

OTE0002
17.09.2019 10:15
 

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with …

OTE0004
11.06.2019 20:45
 

Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks

Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance® (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza® (liraglutide 1.8 mg) …

OTE0001
08.06.2019 17:45
 

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg).

OTE0001
24.03.2019 14:55
 
vorige Seite nächste Seite